The move towards a higher threshold for showing efficacy for new CAR-Ts comes after the FDA loosened the requirements for ...

The reversible BTK inhibitor was at least as effective as AbbVie/Johnson & Johnson's older, non-reversible drug Imbruvica ...

Relation's draw is its 'lab-in-a-loop' process of AI-driven target and drug discovery, in which algorithms are used to find ...

Taking a broader view, ML and other advanced analytics should be used in Medicare – but only to support, never replace, human ...

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

The first cell therapy for severe aplastic anaemia – Gamida Cell's Omisirge – has been approved by the FDA, as positive ...

Globalisation and the growth of emerging markets has created new opportunities to expand the reach for the mature portfolio.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Alfred Olivares, global managing partner, healthcare & ...

Gilead Sciences' Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate ...

The company's BCMAxCD3 bispecific antibody Lynozyfic (linvoseltamab) got its first FDA approval as a fifth-line or later ...

This approach offers an enhanced therapeutic effect with minimal systemic toxicity, addressing one of oncology’s ...

Social determinants of health (SDOH) encompass a wide range of non-medical factors that influence health and well-being.